TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma

被引:0
作者
Cesarina Giallongo
Daniele Tibullo
Giuseppina Camiolo
Nunziatina L. Parrinello
Alessandra Romano
Fabrizio Puglisi
Alessandro Barbato
Concetta Conticello
Gabriella Lupo
Carmelina Daniela Anfuso
Giacomo Lazzarino
Giovanni Li Volti
Giuseppe Alberto Palumbo
Francesco Di Raimondo
机构
[1] University of Catania,Section of Haematology, Department of General Surgery and Medical
[2] University of Catania,Surgical Specialties
[3] EuroMediterranean Institute of Science and Technology,Department of Biomedical and Biotechnological Sciences
[4] Catholic University of Rome,Institute of Biochemistry and Clinical Biochemistry
[5] University of Catania,Department of Medical, Surgical Sciences and Advanced Technologies “G. F. Ingrassia”
来源
Cell Death & Disease | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Inflammation represents a key feature and hallmark of tumor microenvironment playing a major role in the interaction with mesenchymal stromal cells (MSC) in cancer progression. The aim of the present study was to investigate the crosstalk between MSCs and myeloma cells (MM) in the pro-inflammatory microenvironment promoting immune evasion and tumor growth. MSC were collected from patients with diagnosis of MGUS (n = 10), smoldering myeloma (n = 7), multiple myeloma at diagnosis (n = 16), relapse (n = 5) or refractory (n = 3), and from age-matched healthy controls (HC, n = 10) and cultured with peripheral blood mononucleated cells (PBMC) from healthy volunteer donors. Similarly to MM, we showed that MSC from smoldering multiple myeloma (SMM) patients activated neutrophils and conferred an immunosuppressive and pro-angiogenic phenotype. Furthermore, co-cultures of plasma cells (PC) and HC-MSC suggested that such activation is driven by MM cells through the switching into a pro-inflammatory phenotype mediated by toll-like receptor 4 (TLR4). These results were further confirmed using a zebrafish as an immunocompetent in vivo model, showing the role of MM–MSC in supporting PCs engraftment and Th2 response. Such effect was abolished following inhibition of TLR4 signaling in MM–MSC before co-injection with PC. Moreover, the addition of a TLR4 inhibitor in the co-culture of HC-MSC with MM cells prevented the activation of the pro-tumor activity in PC-educated MSC. In conclusion, our study provides evidence that TLR4 signaling plays a key role in MSC transformation by inducing a pro-tumor phenotype associated with a permissive microenvironment allowing immune escape and tumor growth.
引用
收藏
相关论文
共 112 条
[11]  
Ruzehaji N(2010)Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta J. Immunol. 184 5885-332
[12]  
Le Bousse-Kerdiles MC(2018)Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment Cancer Cell 33 634-38108
[13]  
Graham Nicola(2017)Targeting cancer-related inflammation in the era of immunotherapy Immunol. Cell Biol. 95 325-107
[14]  
Qian Bin-Zhi(2003)Toll-like receptor signaling J. Biol. Chem. 278 38105-547
[15]  
Zambetti NA(2008)Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses Stem cells 26 99-85775
[16]  
Mathew E(2012)Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis PLoS ONE 7 541-2375
[17]  
Karnoub AE(2015)TLR4 plays a crucial role in MSC-induced inhibition of NK cell function Biochem Biophys. Res Commun. 464 85764-136
[18]  
Xu WT(2016)Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC) Oncotarget 7 107-2121
[19]  
Bian ZY(2015)Myeloid derived suppressor cells in chronic myeloid leukemia Front Oncol. 5 2367-188
[20]  
Fan QM(2016)Mesenchymal stem cells (MSC) regulate activation of granulocyte-like myeloid derived suppressor cells (G-MDSC) in chronic myeloid leukemia patients PLoS ONE 11 129-210